Deals by medical device companies increase with a focus on cancer, cardiovascular markets
The number of medical device deals have increased from 202 in 2014 to 287 in 2016 according to Cortellis Deals Intelligence (CDI).
In 2016, 13% or 36 deals were focused on cancer while deals on cardiovascular indications were 35 or 12%. Deals on both the therapies have increased significantly from 2014 and 2015.
Cancer deals in 2014 and 2015 were 21 (10%) and 18 (8%) while cardiovascular deals were 17 (8%) and 20 (8%), respectively.
Other deals focused on central nervous system disorders, wound healing, diabetes, respiratory diseases, infections and spinal or musculoskeletal injuries.
Increase in cancer deals could be attributed to the growing biopsy market. University of Texas Health Science Center in Houston signed on with Fluxion Biosciences Inc. in April 2016 to develop a new liquid biopsy for diagnosis and treatment of cancer.
Eigen and Hitachi Medical Systems Europe agreed to distribute the robotic 3-D targeted prostate biopsy device, Artemis, in Europe. Advanced Medical German Co., agreed to distribute Spectrascience’s Wavstat Optical Biopsy System in the Middle East for colorectal cancer.
North America housed 69% (199) of the principal companies conducting deals in 2016, compared with 54% (128) in 2015 and 58% (118) in 2014. In 2017 till March, of the 25 medical device deals, three each are focused on cancer and wound healing, two on central nervous system disorders and one each for diabetes, infection and spinal or musculoskeletal injury, with the rest focused on a variety of miscellaneous indications.
